T-cell therapy in the treatment of post-transplant lymphoproliferative disease.
Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are therefore amenable to T-cell-based immune therapies, such as donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes. In this Review, we describe current approaches of T-cell-based therapies to treat PTLD, and describe strategies that improve the feasibility of such treatment.
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, 1102 Bates Street, Houston, TX 77030, USA. cmbollar@txch.org
Catherine M
CM
Bollard
Cliona M
CM
Rooney
Helen E
HE
Heslop
D019264:Adoptive Transfer; D064987:Cell- and Tissue-Based Therapy; D020031:Epstein-Barr Virus Infections; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology; D013602:T-Lymphocytes, Cytotoxic; D013997:Time Factors
D007166:Immunosuppressive Agents